Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Sullivan (Seattle, United States of America). Valuing the real world benefits of omalizumab. Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives

Member's Comments

No comment yet.

Related content which might interest you: Tele-education in asthma management. What are the benefits? Source: Annual Congress 2012 - Improving education for the healthcare team and patients Year: 2012 Clinical asthma phenotypes in the real world: opportunities and challenges Source: Breathe 2015; 11:186-193 Year: 2015 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Efficacy and safety of omalizumab in real-life practice in India Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Medical therapy for COPD: lessons from the real world Source: Eur Respir J 2002; 20: 797-798 Year: 2002 Italian real-life experience of omalizumab Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Realising the potential of mHealth to improve asthma and allergy care: how to shape the future Source: Eur Respir J, 49 (5) 1700447; 10.1183/13993003.00447-2017 Year: 2017 Interoperability in healthcare: benefits and challenges Source: International Congress 2016 – Implementation of collaborative lung function testing Year: 2016 Exploring the potential benefits of digital health technology for the management of COPD: a qualitative study of patient perceptions Source: ERJ Open Res, 5 (2) 00239-2018; 10.1183/23120541.00239-2018 Year: 2019 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy Source: Eur Respir J, 57 (6) 2100166; 10.1183/13993003.00166-2021 Year: 2021 Costs and benefits: sustainability and transferability Source: ERS Course 2016 - Comprehensive management of ventilator-dependent patients Year: 2016 Describing “real world” COPD patients in primary care in Germany – Findings of the BeoNet-Registry Source: International Congress 2018 – Primary care management of COPD Year: 2018 What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance Source: ERJ Open Res, 7 (1) 00497-2020; 10.1183/23120541.00497-2020 Year: 2021 Anti-IgE: changing lives in clinical practice? Source: Eur Respir Rev 2007; 16: 59-60 Year: 2007 The cost of asthma to patient quality of life and the health service Source: Eur Respir J 2005; 26: Suppl. 49, 672s Year: 2005 Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020